The global neoantigen oncology immunotherapy industry is currently experiencing a dynamic period of growth, fueled by remarkable progress in genomic sequencing and a rising knowledge of the immune system's capability in combating neoplasms. Projections indicate a sustained rise in the future years, driven by therapeutic trials demonstrating promisi